1. To discuss incidence of germline mutations identified in next-generation sequencing platforms
  2. To review currently available data regarding relevance of germline mutations to metastatic disease
  3. To discuss management strategies for incidental germline findings




  1. Review CML treatment with tyrosine kinase inhibitors, including disease monitoring
  2. Understand the potential harms of tyrosine kinase inhibitors on fertility
  3. Discuss optimal management of CML during pregnancies
Session date: 
07/30/2018 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Padma Sheila Rajagopal, MD, MPH and Marquita Nelson, MD